Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the clinical safety and feasibility of T-DM1 after the completion of doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (5-FU)/epirubicin/ cyclophosphamide (FEC) adjuvant/neoadjuvant chemotherapy regimen in HER-2/neu overexpressed/amplified early breast cancer (EBC) patients: • To evaluate the rate of cardiac events during T-DM1 treatment when initiated after completion of anthracycline-containing chemotherapy • To evaluate the safety profile of T-DM1
Critère d'inclusion
- Treatment of HER2 positive adjuvant or neoadjuvant therapy